List of Excipients in Branded Drug ROSUVASTATIN CALCIUM

Generic Drugs Containing ROSUVASTATIN CALCIUM

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY LLC dba Vangard Labs	rosuvastatin calcium	0615-8532	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
NCS HealthCare of KY LLC dba Vangard Labs	rosuvastatin calcium	0615-8532	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY LLC dba Vangard Labs	rosuvastatin calcium	0615-8532	CROSPOVIDONE
NCS HealthCare of KY LLC dba Vangard Labs	rosuvastatin calcium	0615-8532	FERRIC OXIDE RED
NCS HealthCare of KY LLC dba Vangard Labs	rosuvastatin calcium	0615-8532	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in ROSUVASTATIN CALCIUM?

# Of NDCs	Excipient
42	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
34	ANHYDROUS LACTOSE
5	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
1	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
204	CELLULOSE, MICROCRYSTALLINE

Rosuvastatin Calcium Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Rosuvastatin calcium is a mature, high-volume generic statin with limited protection from the original compound patent estate. The commercial opportunity has shifted from conventional immediate-release tablets to differentiated delivery systems, fixed-dose combinations, pediatric and geriatric formats, and excipient technologies that improve manufacturability, stability, or patient adherence. Conventional excipient substitution alone is unlikely to create durable exclusivity, but a well-designed formulation can reduce cost, support regulatory differentiation, and create targeted intellectual-property positions.

What is the regulatory and commercial status of rosuvastatin calcium?

Rosuvastatin calcium is the calcium salt of rosuvastatin, a synthetic HMG-CoA reductase inhibitor used to reduce LDL cholesterol and cardiovascular risk. The reference product is Crestor, originally developed by AstraZeneca and approved by the FDA in 2003 under NDA 021366.[1]

Attribute	Status
Active ingredient	Rosuvastatin calcium
Reference product	Crestor
Reference sponsor	AstraZeneca
FDA approval	2003
Dosage form	Immediate-release oral tablet
Common strengths	5 mg, 10 mg, 20 mg, 40 mg
Therapeutic class	HMG-CoA reductase inhibitor
Regulatory pathway for competitors	ANDA
Biosimilar pathway	Not applicable
Current market structure	Generic-dominated, with branded and authorized-generic supply
Primary commercial barriers	Bioequivalence, API quality, formulation stability, manufacturing cost, channel access

Rosuvastatin calcium does not require a biosimilar strategy because it is a chemically synthesized small molecule. Competitors generally rely on abbreviated new drug applications rather than the biologics license application and biosimilar pathways used for monoclonal antibodies and other biologics.

When did rosuvastatin calcium lose market exclusivity?

U.S. market exclusivity for rosuvastatin calcium has expired. The original commercial opportunity was protected by the compound patent estate, regulatory exclusivity, and later litigation settlements involving generic applicants. Generic rosuvastatin calcium products entered the U.S. market in 2016 after the expiration of key commercial barriers associated with Crestor.[2][3]

The original patent estate included composition-of-matter and related protection for rosuvastatin and its salts. Key patent terms were extended by pediatric exclusivity and were subject to Paragraph IV litigation involving generic applicants. The commercially relevant compound protection is no longer a barrier to ordinary generic entry.

What is the Orange Book status of Crestor?

The FDA Orange Book remains the controlling source for currently listed patents, exclusivity, therapeutic-equivalence codes, and approved products.[2] Crestor is no longer protected by active commercial exclusivity that prevents ordinary generic rosuvastatin calcium entry. The relevant practical question is no longer whether a manufacturer can enter the molecule, but whether it can:

• obtain and maintain an AB-rated product;
• manufacture at a competitive cost;
• meet dissolution and content-uniformity requirements;
• manage API supply and impurity controls;
• differentiate the product in retail, institutional, or specialty channels.

Orange Book listings can change through patent delisting, expiration, corrections, and product-status updates. A current diligence review should rely on the live FDA database rather than historical Crestor patent listings.

What excipients are used in rosuvastatin calcium tablets?

The reference product uses a conventional immediate-release tablet platform. Crestor labeling identifies excipients that include lactose monohydrate, microcrystalline cellulose, tribasic calcium phosphate, crospovidone, magnesium stearate, hypromellose, titanium dioxide, ferric oxides, and triacetin, with colorant composition varying by strength.[1]

Excipient function	Representative excipients	Commercial purpose
Diluent	Lactose monohydrate, microcrystalline cellulose, tribasic calcium phosphate	Tablet mass, compressibility, dose uniformity
Disintegrant	Crospovidone	Rapid breakup and dissolution
Lubricant	Magnesium stearate	Ejection from tooling and reduced sticking
Glidant	Colloidal silicon dioxide, where used	Powder flow and content uniformity
Film former	Hypromellose	Tablet coating and mechanical protection
Plasticizer	Triacetin	Film flexibility
Opacifier	Titanium dioxide	Appearance and light protection
Colorant	Ferric oxide pigments	Strength identification and product branding

A generic formulation does not need to duplicate Crestor’s excipient composition. It must meet applicable quality, bioequivalence, stability, dissolution, and labeling requirements. The formulation must also account for the physicochemical behavior of rosuvastatin calcium and the selected manufacturing process.

How should formulators select excipients for rosuvastatin calcium?

The central development issue is the balance between dissolution performance, tablet robustness, API loading, and stability. Rosuvastatin calcium is generally handled as a low-dose, immediate-release API in tablets. The formulation therefore must distribute a small quantity of drug consistently through a relatively large excipient matrix.

Diluent strategy

Microcrystalline cellulose is useful where direct compression, compactibility, and tablet strength are priorities. Lactose can improve powder economics and tablet mass but may require evaluation for chemical compatibility, moisture sensitivity, and supplier variability. Tribasic calcium phosphate may provide useful compression and density characteristics, but its alkalinity and calcium content should be evaluated against API stability and dissolution behavior.

For direct compression, a co-processed diluent containing microcrystalline cellulose and a compressible carbohydrate can reduce segregation and improve tablet tensile strength. For wet granulation, lactose, microcrystalline cellulose, or mannitol can be selected according to granule density, drying behavior, and dissolution targets.

Disintegrant strategy

Crospovidone, croscarmellose sodium, and sodium starch glycolate can all support immediate-release performance. Crospovidone is commonly attractive for rapid wicking and low gelling risk. Croscarmellose sodium may provide strong swelling but can be sensitive to compression force and formulation moisture. Sodium starch glycolate can produce rapid swelling but may create variability if overused or inadequately dispersed.

The optimal level should be determined by dissolution and tablet-strength data rather than by direct substitution of the reference product. Overcompression can reduce porosity and delay disintegration even when the nominal disintegrant concentration is adequate.

Lubricant strategy

Magnesium stearate is effective but can impair wetting and dissolution when over-lubrication occurs. Blending time, lubricant grade, specific surface area, and shear history should be controlled. Alternative lubricants such as sodium stearyl fumarate may support faster dissolution or reduce sensitivity to over-lubrication, although they can alter ejection behavior and tablet appearance.

Coating strategy

Film coating is commercially useful for color coding, swallowability, light protection, and product differentiation. Hypromellose-based coatings remain the standard platform. Polyvinyl alcohol systems can support aqueous coating and efficient film formation. For pediatric or orally disintegrating products, coating weight must be controlled to avoid slowing disintegration or creating an unpleasant mouthfeel.

What formulation patents could protect rosuvastatin calcium products?

A conventional tablet containing standard excipients is usually difficult to protect with a strong formulation patent. A patent position is more credible when the formulation solves a defined technical problem and produces measurable performance benefits.

Potentially protectable subject matter includes:

• a specific excipient ratio that improves dissolution across storage conditions;
• a stabilized rosuvastatin calcium composition with controlled pH or moisture;
• a solid dispersion or amorphous formulation with improved dissolution;
• an orally disintegrating tablet with defined disintegration and friability limits;
• a multiparticulate or sprinkle formulation;
• a fixed-dose combination with a second cardiovascular agent;
• a manufacturing process that controls polymorph, particle size, or impurity formation;
• a coated particle or granule that separates rosuvastatin from an incompatible excipient;
• a formulation that reduces food-effect variability or supports administration through enteral tubes.

Patent strength depends on unexpected results, claim breadth, enablement, and the availability of design-around routes. A narrow excipient-ratio claim can be commercially useful if it is difficult to reproduce without infringing and if the product has a meaningful distribution advantage. It is less valuable when competitors can substitute a different disintegrant, alter granulation, or use another salt or particle-engineering approach.

What commercial opportunities exist beyond standard tablets?

Orally disintegrating and chewable products

Low-dose rosuvastatin calcium is suitable for orally disintegrating tablets, mini-tablets, and chewable formats. These products may target patients with dysphagia, older adults, and pediatric populations. The development challenge is taste masking. Ion-exchange resins, polymeric coatings, lipid barriers, and sweetener-flavor systems can reduce bitterness, but each may affect release.

An ODT can support a 505(b)(2) strategy when the product introduces a meaningful dosage-form or administration benefit and is not simply an ANDA-equivalent tablet. The regulatory pathway depends on the extent of formulation and clinical differences.

Sprinkle and multiparticulate formulations

Granules, pellets, or coated particles administered with soft food can address swallowing limitations. Multiparticulates can also support dose flexibility and reduce dependence on tablet splitting. The main technical risks are content uniformity, moisture uptake, coating integrity, and maintaining immediate release after administration with food.

Fixed-dose combinations

Rosuvastatin is commercially compatible with other cardiovascular therapies, including ezetimibe, amlodipine, antihypertensive agents, and antiplatelet therapies. Fixed-dose combinations can improve adherence and create a broader commercial proposition than an excipient-only innovation.

The regulatory and intellectual-property analysis must address:

• each active ingredient’s patent status;
• drug-drug compatibility;
• dissolution of each component;
• pharmacokinetic interaction risk;
• dose flexibility;
• labeling and titration constraints.

Combination products can have stronger commercial differentiation than a reformulated rosuvastatin monoproduct, but they face more complex development and supply-chain requirements.

Pediatric and geriatric products

Pediatric formulations can use lower-strength mini-tablets, oral granules, suspensions, or ODTs. Geriatric products can emphasize easy swallowing, reduced tablet size, and compatibility with feeding tubes. These segments may support higher gross margins than commodity tablets but have smaller volumes and more demanding taste, stability, and administration studies.

Excipient platform licensing

Excipient suppliers can create value through:

• co-processed direct-compression systems;
• low-moisture or low-peroxide excipient grades;
• taste-masking polymers;
• fast-disintegrating matrices;
• continuous-manufacturing excipient systems;
• functional coatings;
• stability-enhancing packaging and desiccant systems.

For a mature generic API, the strongest licensing proposition is usually a reproducible manufacturing advantage rather than a broad claim that the excipient merely improves tablet performance.

What manufacturing and intellectual-property barriers remain?

The API is commercially available, but quality and supply risks remain material. Rosuvastatin calcium manufacturers must control particle-size distribution, salt form, residual solvents, elemental impurities, related substances, and batch-to-batch assay performance. API particle engineering can materially affect blend uniformity and dissolution.

Manufacturing barriers include:

1. Low-dose content uniformity in high-speed tableting.
2. Sensitivity to lubricant level and blending time.
3. Compression-related dissolution changes.
4. API-excipient compatibility during accelerated stability testing.
5. Coating variability across multiple strengths.
6. Supplier qualification for critical excipients.
7. Stability of the calcium salt under heat and humidity.
8. Packaging requirements for moisture and light control.

A formulation patent does not eliminate the need to establish pharmaceutical equivalence. Generic manufacturers must still demonstrate equivalence to the reference product under FDA requirements, including comparative dissolution and bioequivalence where applicable.[4]

How does rosuvastatin calcium compare with atorvastatin and other statins?

Product	Market position	Formulation opportunity	Patent risk today
Rosuvastatin calcium	High-potency, generic-dominated	ODT, low-dose flexibility, combinations, multiparticulates	Low for ordinary tablets
Atorvastatin calcium	Very high-volume generic statin	Combinations and adherence formats	Low for ordinary tablets
Ezetimibe combinations	Combination-driven	Fixed-dose cardiovascular products	Depends on product and jurisdiction
Simvastatin	Older, lower-potency statin	Limited premium differentiation	Low
Pravastatin	Older statin with distinct tolerability positioning	Pediatric and adherence formats	Low

Rosuvastatin retains commercial value because of its potency, broad prescribing base, and use in intensive LDL reduction. The opportunity is stronger in differentiated delivery and combination products than in another undifferentiated 5 mg or 10 mg immediate-release tablet.

Which companies are challenging or competing with Crestor?

Competition comes primarily from generic manufacturers and authorized-generic suppliers rather than biosimilar developers. Companies that have marketed or sought approval for rosuvastatin products have included large generic manufacturers such as Teva, Sandoz, Watson/Actavis, Mylan, Lupin, Dr. Reddy’s, and Sun Pharma, among others. Market participation varies by country, product strength, supply status, and time.

The commercial competitive set includes:

• ANDA manufacturers selling AB-rated tablets;
• contract development and manufacturing organizations;
• API suppliers;
• combination-product developers;
• specialty companies offering ODT, chewable, or sprinkle products;
• branded-generic companies competing through packaging and distribution.

What is the revenue exposure and commercial outlook?

Crestor generated multibillion-dollar annual sales before generic erosion. AstraZeneca reported Crestor sales of approximately $6.6 billion in 2011, making it one of the company’s largest products before loss of exclusivity.[5] Current revenue has migrated from the innovator to generic manufacturers, wholesalers, pharmacies, and combination-product developers.

The largest volume opportunity remains standard tablets. The higher-margin opportunity is in products that solve a specific administration or adherence problem. A commercially credible product should offer at least one of the following:

• lower manufacturing cost;
• superior tablet robustness;
• improved dissolution consistency;
• easier administration;
• dose flexibility;
• combination convenience;
• lower freight or packaging cost;
• a defensible formulation patent;
• access to an underserved geographic market.

What geographic opportunities exist for rosuvastatin calcium?

The United States is a mature generic market with strong price competition. Europe, Japan, China, India, Latin America, and emerging markets may offer different opportunities because approval timing, reimbursement, substitution rules, and local manufacturing requirements vary.

Geographic strategy should assess:

• local registration of rosuvastatin calcium versus rosuvastatin;
• reference-product requirements;
• bioequivalence standards;
• mandatory local clinical or manufacturing data;
• public procurement pricing;
• local excipient and API sourcing;
• patent status by country;
• trademark and packaging restrictions;
• pediatric and combination-product demand.

A formulation patent must be assessed country by country. U.S. patent expiry does not establish freedom to operate in Europe, Japan, China, India, Brazil, or other markets.

Key Takeaways

• Rosuvastatin calcium is a mature, generic-dominated small-molecule market.
• Ordinary immediate-release tablets have limited differentiation and intense price competition.
• The reference formulation uses conventional excipients, including lactose, microcrystalline cellulose, tribasic calcium phosphate, crospovidone, magnesium stearate, and film-coating materials.
• The strongest excipient opportunities involve dissolution control, stability, content uniformity, taste masking, and manufacturing efficiency.
• ODTs, sprinkle products, mini-tablets, chewables, and fixed-dose combinations offer better commercial differentiation than standard tablets.
• Conventional excipient substitution is unlikely to support strong exclusivity without unexpected performance data.
• There is no biosimilar pathway because rosuvastatin calcium is a chemically synthesized small molecule.
• Current diligence should use the FDA Orange Book, current approved labeling, country-specific patent registers, and live litigation records.
• The highest-value IP opportunities are formulation, combination, manufacturing-process, and delivery-system claims.

FAQs

Can rosuvastatin calcium be formulated as an oral suspension?

Yes. An oral suspension can target pediatric, geriatric, or dysphagic patients. The formulation must control sedimentation, redispersibility, dose uniformity, palatability, preservative performance, and chemical stability.

Does rosuvastatin calcium require a solubility-enhancing excipient?

Not necessarily. A conventional immediate-release tablet can be developed with standard diluents and disintegrants. Solubility-enhancing technologies become more relevant for ODTs, suspensions, low-volume dosage forms, or formulations that seek faster or more robust dissolution.

Are excipient patents enough to block generic rosuvastatin calcium entry?

Usually not. Generic entry can rely on a non-infringing excipient system if the product meets regulatory requirements. A blocking position requires broad, valid, enforceable claims that cover commercially practical alternatives.

Can a rosuvastatin calcium product qualify for a 505(b)(2) application?

Potentially. A materially different dosage form, route, or administration method may support a 505(b)(2) pathway. The regulatory strategy depends on the extent of reliance on the reference product and the clinical evidence required for the proposed differences.

Is rosuvastatin calcium suitable for continuous manufacturing?

Yes. Its low dose makes blend uniformity and feeding control important, but continuous manufacturing can improve process consistency, reduce hold times, and support real-time quality monitoring. Development must establish reliable API feeding, segregation control, and content-uniformity performance.

References

1. U.S. Food and Drug Administration. (2023). Crestor (rosuvastatin calcium) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2016). FDA approves first generic versions of Crestor.
4. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.
5. AstraZeneca PLC. (2011). Annual report and form 20-F 2011.